Autologous tumour infiltrating lymphocyte-Interleukin-7 cell therapies (Adaptimmune)

N/A

Report date: 2024/12/23 09:35:54

Base Information

Drug NameAutologous tumour infiltrating lymphocyte-Interleukin-7 cell therapies (Adaptimmune)
Drug Alias NameTILIL-7
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune LlcHerlev Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A